Obinutuzumab Equals Rituximab in Relapsed Indolent NHL
December 13, 2011|Hematology and Oncology
Author and Disclosure Information
FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY
Phase III trials with obinutuzumab are underway.
The study was supported by Roche. Dr. Sehn and three coauthors disclosed consulting and receiving honoraria and/or research funding from Roche/Genentech. Two coauthors are Roche employees. Dr. Hochberg has received consulting fees or research support from the company.
*Correction, 12/15/2011: The best overall response rate by independent review was incorrectly stated for rituximab. This version has been updated.
